Phase I, Multicenter, Open-label, Clinical and Pharmacokinetic Study of PM01183 in Combination With Irinotecan in Pretreated Patients With Selected Advanced Solid Tumors

Trial Profile

Phase I, Multicenter, Open-label, Clinical and Pharmacokinetic Study of PM01183 in Combination With Irinotecan in Pretreated Patients With Selected Advanced Solid Tumors

Recruiting
Phase of Trial: Phase I

Latest Information Update: 05 Oct 2017

At a glance

  • Drugs Lurbinectedin (Primary) ; Irinotecan
  • Indications Adenocarcinoma; Colorectal cancer; Endometrial cancer; Gastric cancer; Glioblastoma; Neuroendocrine tumours; Ovarian cancer; Pancreatic cancer; Small cell lung cancer; Soft tissue sarcoma; Solid tumours
  • Focus Adverse reactions
  • Sponsors PharmaMar
  • Most Recent Events

    • 28 Sep 2017 Planned End Date changed from 1 Aug 2019 to 1 May 2020.
    • 28 Sep 2017 Planned primary completion date changed from 1 Aug 2018 to 1 May 2019.
    • 20 May 2016 Status changed from not yet recruiting to recruiting, according to a PharmaMar media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top